PAUL V MAIER
CIK 1182615 · Chief Financial Officer · last filed 2026-01-14
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$1.89M
Companies
8
Total Filings
129
Lifetime Open-Market Net
$33.6K
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ETON | Director | 59,745 | $31.59 | $1.89M | $30.0K | 9 | 2026-01-14 |
| Ambrx Biopharma, Inc. (AMAM) Delisted | Director | 85,000 | $28.00 | $2.38M | $0 | 3 | 2024-03-07 |
| Qualigen Therapeutics, Inc. (RTTR) Delisted | Director | — | — | — | $0 | 5 | 2020-01-17 |
| MABVAX THERAPEUTICS HOLDINGS, INC. (MBVX) Delisted | Director | 23,063 | — | — | -$30.3K | 12 | 2018-04-04 |
| SEELOS THERAPEUTICS, INC. (APRI) Delisted | Director | 13,854 | — | — | $0 | 11 | 2018-01-08 |
| SEQUENOM INC (SQNM) Delisted | Chief Financial Officer | 76,927 | — | — | $28.6K | 18 | 2014-02-12 |
| PURE BIOSCIENCE, INC. (PURE) Delisted | Director | 69,110 | — | — | $0 | 2 | 2012-08-02 |
| Talon Therapeutics, Inc. (HNAB) Delisted | Director | 7,000 | — | — | $5.2K | 4 | 2009-02-26 |
Recent Filings · Page 5 of 13
129 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2017-04-04 | MABVAX THERAPEUTICS HOLDINGS, INC. (MBVX) Delisted | Exer (M) | +1,543 | $0 | EDGAR |
| 2017-04-03 | — | Grant (A) | +4,642 | $0 | |
| 2017-01-06 | SEELOS THERAPEUTICS, INC. (APRI) Delisted | Grant (A) | +11,250 | $0 | EDGAR |
| 2017-01-03 | MABVAX THERAPEUTICS HOLDINGS, INC. (MBVX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2016-12-30 | — | Grant (A) | +7,523 | $0 | |
| 2016-11-30 | Qualigen Therapeutics, Inc. (RTTR) Delisted | Grant (A) | — | $0 | EDGAR |
| 2016-10-14 | — | Grant (A) | +1,334 | $0 | |
| 2016-10-03 | SEELOS THERAPEUTICS, INC. (APRI) Delisted | Grant (A) | +10,715 | $3.6K | EDGAR |
| 2016-09-30 | — | Grant (A) | +4,391 | $0 | |
| 2016-08-30 | MABVAX THERAPEUTICS HOLDINGS, INC. (MBVX) Delisted | Grant (A) | — | $0 | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.